Results 21 to 30 of about 25,862 (171)

Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children

Frontiers in Pediatrics, 2022
BackgroundPediatric patients have significant interindividual variability in voriconazole exposure. The aim of the study was to identify factors associated with voriconazole concentrations and dose requirements to achieve therapeutic concentrations in ...
Juan Chen, Ying Wu, Yuelin He, Xiaoqin Feng, Yuqiong Ren, Shiting Liu   +5 more
doaj   +1 more source

Efficacy of voriconazole on leishmaniasis by Leishmania major: An in vitro and in vivo study

Asian Pacific Journal of Tropical Medicine, 2018
Objective: To appraise the activity of voriconazole against Leishmania major (L. major) in vitro and its effectiveness on wound regeneration in cutaneous leishmaniasis in BALB/c mice.
Ahmad Oryan, Somayeh Bahrami, Effat Bemani   +2 more
doaj   +1 more source

Drug reservoir function of voriconazole impregnated human amniotic membrane: An in vitro study

Indian Journal of Ophthalmology, 2021
Purpose: Earlier our group has demonstrated the drug reservoir function of the human amniotic membrane (HAM) using stable moxifloxacin and fortified cefazolin ophthalmic formulations and found it as a suitable tool to deliver drugs for an extended ...
Manali Hazarika, Namperumalsamy Venkatesh Prajna, Srinivasan Senthilkumari   +2 more
doaj   +1 more source

A rare case of voriconazole-induced vertebral periostitis in a patient with invasive aspergillus spondylodiscitis

Indian Spine Journal, 2022
The author illustrates the first ever reported case of voriconazole-induced periostitis of vertebral body. A 66-year-old immunocompetent male patient was diagnosed with multilevel invasive aspergillus spondylodiscitis of dorsal spine and was put on long ...
Alok Jain, Aaditya Kashikar, Premik B Nagad, Shekhar Y Bhojraj   +3 more
doaj   +1 more source

Voriconazole

Reactions Weekly, 2006
Voriconazole (VRZ) is a second-generation triazole antifungal agent active against many species of Aspergillus and Candida and acts by inhibiting ergosterol synthesis. VRZ has less nephrotoxicity and less infusion-related toxicity than that of Amphotericin B. Oral and parental formulation have similar pharmacokinetics and thus oral formulation shortens
Rahul, Naithani, Rajat, Kumar
openaire   +3 more sources

In-vitro Antifungal Activities of Kombucha Tea Culture Supernatant Combined with Voriconazole against Vulvovaginal Candidiasis Clinical Isolates

Journal of Health Science and Medical Research (JHSMR), 2023
Objective: To investigate the antifungal activity of voriconazole, with and without Kombucha tea culture, against Candida strains isolated from vulvovaginal candidiasis.  Material and Methods: The study included 150 females, within child-bearing periods,
Rasha H. Bassyouni, Fatma AboElnaga Ahmed, Ahmed A. Ismaiel, Abdelsamie Abdelmoneim, Haitham Badran, Mazen A. El Zahry, Reham Ali Dwedar, Ahmed Ashraf Wegdan   +7 more
doaj   +1 more source

Voriconazole and the liver

World Journal of Hepatology, 2015
Voriconazole is an azole useful for the prophylaxis and the treatment of aspergillosis and other fungal infections in immunosuppressed subjects, as those found in aplasia after aggressive polychemotherapy treatments, after hematopoietic stem cell, liver or lung transplantation.
openaire   +2 more sources

Supratherapeutic drug concentration triggers: A novel data‐driven approach to assess their value for medication safety surveillance in intensive care

British Journal of Clinical Pharmacology, EarlyView.
Aims Electronic triggers (e‐triggers) are used as screening signals to detect potential adverse drug events (ADEs) and offer an effective system level approach for medication safety surveillance. Their clinical utility is typically evaluated through time‐consuming manual chart review by experts, limiting implementation.
Anne Paulien Langermans, Izak A. R. Yasrebi‐de Kom, Dylan Wayne de Lange, Nicolette Fransisca de Keizer, Joanna E. Klopotowska, on behalf of the RESCUE Study group, C. S. C. Bouman, E. N. van Roon, P. F. Schutte, J. ten Cate, D. van Balen, S. Hendriks, C. Lau, W. J. Vermeijden, A. Beishuizen, J. B. Masselink, P. E. Spronk, H. J. M. van Kan, P. W. de Feiter, E. J. Wils, A. Wieringa, A. J. Valkenburg, W. M. van den Bergh, M. H. Renes, W. Bult, E. de Jonge, M. Hoeksema, E. J. Wesselink, I. M. Purmer, B. E. Bosma, S. H. W. van Bree, H. J. W. Lammers, R. J. Bosman, E. J. F. Franssen, A. Karakus, M. Sigtermans, E. M. Kuck, D. A. Dongelmans, M. J. H. Aries, E. V. Uijtendaal, M. C. Reuland   +40 more
wiley   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Voriconazole: a review of adjustment programs guided by therapeutic drug monitoring

Frontiers in Pharmacology
ObjectivesExploring adjustments to the voriconazole dosing program based on therapeutic drug monitoring results to implement individualized therapy.MethodsPubMed and Embase were systematically searched to obtain study about voriconazole dose adjustment ...
Li Jiang, Zhiqiang Lin
doaj   +1 more source